BioNote Inc.
BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-… Read more
BioNote Inc. (377740) - Net Assets
Latest net assets as of March 2023: ₩1.55 Trillion KRW
Based on the latest financial reports, BioNote Inc. (377740) has net assets worth ₩1.55 Trillion KRW as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.73 Trillion) and total liabilities (₩188.76 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩1.55 Trillion |
| % of Total Assets | 89.11% |
| Annual Growth Rate | 143.64% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 197.96 |
BioNote Inc. - Net Assets Trend (2019–2022)
This chart illustrates how BioNote Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioNote Inc. (2019–2022)
The table below shows the annual net assets of BioNote Inc. from 2019 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | ₩1.60 Trillion | +26.35% |
| 2021-12-31 | ₩1.27 Trillion | +98.28% |
| 2020-12-31 | ₩638.70 Billion | +477.60% |
| 2019-12-31 | ₩110.58 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioNote Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2719.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.47 Trillion | 91.62% |
| Other Components | ₩134.12 Billion | 8.38% |
| Total Equity | ₩1.60 Trillion | 100.00% |
BioNote Inc. Competitors by Market Cap
The table below lists competitors of BioNote Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Greenland Resources Inc
PINK:GRLRF
|
$52.18 Million |
|
LONGBOAT ENERGY LS-10
F:8YG
|
$52.18 Million |
|
Taiwan Kong King Co Ltd
TWO:3093
|
$52.18 Million |
|
ChainSea Information Integration Co.,Ltd.
TWO:6898
|
$52.19 Million |
|
Betmakers Technology Group Ltd
PINK:TPBTF
|
$52.16 Million |
|
Korea Parts & Fasteners Co.Ltd
KQ:024880
|
$52.16 Million |
|
Alpha Technology Group Limited Ordinary Shares
NASDAQ:ATGL
|
$52.14 Million |
|
Zenix Robotics Co.,Ltd
KQ:381620
|
$52.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioNote Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 1,266,407,103,010 to 1,600,152,081,930, a change of 333,744,978,920 (26.4%).
- Net income of 307,797,756,620 contributed positively to equity growth.
- Dividend payments of 49,958,929,630 reduced retained earnings.
- New share issuances of 73,280,000,000 increased equity.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩307.80 Billion | +19.24% |
| Dividends Paid | ₩49.96 Billion | -3.12% |
| Share Issuances | ₩73.28 Billion | +4.58% |
| Other Changes | ₩2.63 Billion | +0.16% |
| Total Change | ₩- | 26.35% |
Book Value vs Market Value Analysis
This analysis compares BioNote Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.34x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.05x to 0.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩1063.69 | ₩5370.00 | x |
| 2020-12-31 | ₩6143.90 | ₩5370.00 | x |
| 2021-12-31 | ₩12182.14 | ₩5370.00 | x |
| 2022-12-31 | ₩15706.85 | ₩5370.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioNote Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.24%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 64.17%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.10x
- Recent ROE (19.24%) is below the historical average (43.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 18.64% | 51.47% | 0.31x | 1.18x | ₩9.56 Billion |
| 2020 | 82.70% | 83.65% | 0.74x | 1.34x | ₩464.36 Billion |
| 2021 | 53.03% | 107.91% | 0.42x | 1.17x | ₩544.92 Billion |
| 2022 | 19.24% | 64.17% | 0.27x | 1.10x | ₩147.78 Billion |
Industry Comparison
This section compares BioNote Inc.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioNote Inc. (377740) | ₩1.55 Trillion | 18.64% | 0.12x | $52.17 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |